Literature DB >> 14744764

An Msh2 point mutation uncouples DNA mismatch repair and apoptosis.

Diana P Lin1, Yuxun Wang, Stefan J Scherer, Alan B Clark, Kan Yang, Elena Avdievich, Bo Jin, Uwe Werling, Tchaiko Parris, Naoto Kurihara, Asad Umar, Raju Kucherlapati, Martin Lipkin, Thomas A Kunkel, Winfried Edelmann.   

Abstract

Mutations in the human DNA mismatch repair gene MSH2 are associated with hereditary nonpolyposis colorectal cancer as well as a significant proportion of sporadic colorectal cancer. The inactivation of MSH2 results in the accumulation of somatic mutations in the genome of tumor cells and resistance to the genotoxic effects of a variety of chemotherapeutic agents. Here we show that the DNA repair and DNA damage-induced apoptosis functions of Msh2 can be uncoupled using mice that carry the G674A missense mutation in the conserved ATPase domain. As a consequence, although Msh2(G674A) homozygous mutant mice are highly tumor prone, the onset of tumorigenesis is delayed as compared with Msh2-null mice. In addition, tumors that carry the mutant allele remain responsive to treatment with a chemotherapeutic agent. Our results indicate that Msh2-mediated apoptosis is an important component of tumor suppression and that certain MSH2 missense mutations can cause mismatch repair deficiency while retaining the signaling functions that confer sensitivity to chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744764     DOI: 10.1158/0008-5472.can-03-2957

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  84 in total

Review 1.  Mouse models of inherited cancer syndromes.

Authors:  Sohail Jahid; Steven Lipkin
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

2.  The predicted truncation from a cancer-associated variant of the MSH2 initiation codon alters activity of the MSH2-MSH6 mismatch repair complex.

Authors:  Jennifer L Cyr; Graham D Brown; Jennifer Stroop; Christopher D Heinen
Journal:  Mol Carcinog       Date:  2011-08-11       Impact factor: 4.784

3.  Biochemical analysis of the human mismatch repair proteins hMutSα MSH2(G674A)-MSH6 and MSH2-MSH6(T1219D).

Authors:  Hui Geng; Miho Sakato; Vanessa DeRocco; Kazuhiko Yamane; Chunwei Du; Dorothy A Erie; Manju Hingorani; Peggy Hsieh
Journal:  J Biol Chem       Date:  2012-01-25       Impact factor: 5.157

4.  Phosphorylated hMSH6: DNA mismatch versus DNA damage recognition.

Authors:  Saravanan Kaliyaperumal; Steve M Patrick; Kandace J Williams
Journal:  Mutat Res       Date:  2010-10-28       Impact factor: 2.433

5.  Mismatch repair proteins are activators of toxic responses to chromium-DNA damage.

Authors:  Elizabeth Peterson-Roth; Mindy Reynolds; George Quievryn; Anatoly Zhitkovich
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

6.  Nuclear reorganization of DNA mismatch repair proteins in response to DNA damage.

Authors:  Adam S Mastrocola; Christopher D Heinen
Journal:  DNA Repair (Amst)       Date:  2009-12-08

7.  Small molecule induction of MSH2-dependent cell death suggests a vital role of mismatch repair proteins in cell death.

Authors:  Aksana Vasilyeva; Jill E Clodfelter; Brian Rector; Thomas Hollis; Karin D Scarpinato; Freddie R Salsbury
Journal:  DNA Repair (Amst)       Date:  2008-11-12

8.  Disruption of a mitochondrial MutS DNA repair enzyme homologue confers drug resistance in the parasite Toxoplasma gondii.

Authors:  Erin M Garrison; Gustavo Arrizabalaga
Journal:  Mol Microbiol       Date:  2009-03-04       Impact factor: 3.501

9.  Rapid DNA double-strand breaks resulting from processing of Cr-DNA cross-links by both MutS dimers.

Authors:  Mindy F Reynolds; Elizabeth C Peterson-Roth; Ivan A Bespalov; Tatiana Johnston; Volkan M Gurel; Haley L Menard; Anatoly Zhitkovich
Journal:  Cancer Res       Date:  2009-01-13       Impact factor: 12.701

Review 10.  DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets.

Authors:  Long Shan Li; Julio C Morales; Martina Veigl; David Sedwick; Sheldon Greer; Mark Meyers; Mark Wagner; Richard Fishel; David A Boothman
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.